CRISPR Therapeutics Reports Mixed Cancer Trial Results
A first look at a revolutionary new cancer therapy produced mixed results that impressed oncologists, but depressed shares of CRISPR Therapeutics (NASDAQ: CRSP) -- the company developing it. Treatment with the candidate, CTX110, led to complete remission for two out of the four patients who received the third-highest dose of the CAR-T therapy. Sadly, one patient who had been treated with the highest dosage died from apparently unrelated complications after treatment with CTX110 helped him to achieve complete remission.
The Carbon trial enrolled non-Hodgkin's lymphoma patients with disease that either had recurred or never responded to multiple lines of therapy. That any of these patients responded to CTX001 was remarkable, but investors were disappointed with the level of efficacy, which didn't seem competitive with existing treatments that take a similar approach.
Image source: Getty Images.
Source Fool.com
